Twist Bioscience Corporation (Nasdaq: TWST) shares rose 4.34% to $144.10 at the market open on September 16, 2026, as the synthetic DNA and biotechnology company continues to operate across therapeutics, diagnostics, agriculture, data storage, and research markets. The stock has gained approximately 6.97% over the five-day period shown in the market data.
Market Performance
Twist Bioscience opened at $142.28 and traded between $142.28 and $148.50 in the session shown. The previous close was $138.10, representing a $6.00 increase at the time of the displayed market update.
Trading volume stood at approximately 509,079 shares, compared with an average volume of approximately 1.70 million shares. Twist Bioscience had an intraday market capitalization of approximately $9.57 billion.
The stock’s 52-week range was $23.30 to $155.44. The company reported trailing twelve-month EPS of -$2.28, while the one-year target estimate shown was $106.25. The stock’s beta was listed at 2.22.
Company Background
Twist Bioscience manufactures and sells synthetic DNA-based products. Its offerings include synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals and materials, food and agriculture, data storage, and academic research.
The company also provides oligo pools used in targeted next-generation sequencing, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, and other applications. Its portfolio includes immunoglobulin G proteins for customers focused on drug discovery and development.
Twist also offers next-generation sequencing tools, including library preparation kits, human exome kits, fixed and custom panels, and alliance panels used in diagnostic testing, population genetics research, biomarker discovery, translational research, microbiology, and applied markets research.
The company additionally provides methylation detection kits, RNA sequencing solutions, respiratory viral controls, research panels, precision DNA libraries for antibody engineering, and antibody optimization solutions.
Management and Corporate Profile
Twist Bioscience is led by Co-Founder, Board Chair and CEO Dr. Emily Marine Leproust, with Dr. Patrick John Finn serving as President and COO. Adam Laponis is the company’s Chief Financial Officer.
The management team also includes Chief Legal Officer and Corporate Secretary Dennis Cho, Senior Vice President of Human Resources Paula Green, Vice President and Chief Accounting Officer Robert E. Werner, Chief Technology Officer Siyuan Chen, Chief Information Officer Dr. Michael Fero, Chief Scientific Officer Dr. Colby Souders, and Senior Vice President of Sales and Support Nicole Moreno.
Founded in 2013, Twist Bioscience is headquartered in South San Francisco, California, and has approximately 979 full-time employees.
Market Context & Opportunities
Twist Bioscience operates across several areas of biotechnology and synthetic biology, with its DNA-based products supporting applications ranging from drug discovery and diagnostics to agricultural research, sequencing, and advanced research.
Its products are also designed for specialized applications such as CRISPR gene editing, DNA data storage, antibody engineering, and sequencing workflows. The breadth of these applications gives the company exposure to multiple areas of biotechnology and life sciences research.
Twist also has a strategic collaboration with bitBiome Inc., according to the company description shown in the provided market profile.
Risks & Challenges
Twist Bioscience continues to report negative trailing twelve-month EPS of $2.28, indicating that the company has not generated positive earnings on a trailing basis. Its stock also has a relatively wide 52-week range of $23.30 to $155.44, reflecting substantial movement in its market valuation.
The company’s broad exposure to biotechnology, research, diagnostics, and advanced applications also means its operating performance is tied to demand across multiple specialized markets.
The next earnings date shown in the market profile is November 16, 2026.
Closing Paragraph
Twist Bioscience shares were trading at $144.10, up 4.34%, in the market update shown, giving the company an intraday market capitalization of approximately $9.57 billion. Its synthetic DNA platform supports applications across therapeutics, diagnostics, sequencing, agriculture, research, and other advanced fields. With negative trailing earnings and a stock price near its 52-week high, investors will continue to monitor the company’s financial performance and development across its broad biotechnology platform.
